Autotelic Bio Inc. has divulged thiazole derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer.
A team at 1st Bio Therapeutics Inc. has identified indazoles acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Chengdu Easton Biopharmaceuticals Co. Ltd. has synthesized aminopyridine derivatives acting as CDK9/cyclin T1 inhibitors reported to be useful for the treatment of cancer.
Researchers from Biolexis Therapeutics Inc. presented the development of a potent and highly selective CDK9 inhibitor, BLX-3030, and its analogues for the treatment of N-Myc and c-Myc-driven cancers.
Y-Mabs Therapeutics Inc. has received FDA clearance of its IND application for CD38-SADA, the company’s second program within its SAYA Y-PRIT (Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy) theranostic platform.
Researchers from Astellas Pharma Inc. presented preclinical data for the novel small-molecule diacylglycerol kinase ζ (DGKζ) inhibitor ASP-1570, currently in phase I development for the treatment of solid tumors (NCT05083481).
Monte Rosa Therapeutics Inc. has entered into a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop molecular glue degraders against targets in cancer and neurological diseases previously considered impossible to drug.
KRAS is a GTP-binding protein involved in cell growth control that requires post-translational farnesylation to be active. KRAS G12D mutations are mostly associated with pancreatic, colorectal and non-small-cell lung cancers and occur less commonly in other cancers. There are currently no therapies approved to specifically target this mutation.
Jazz Pharmaceuticals plc has described tricyclic phthalazines acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
RSS
